Alpha-MSH raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-10. Anything still debated is marked as such rather than presented as settled.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Faced with the threat of growing German Nazism, Italian fascism, Japanese militarism, and a world war, the Western Allies and the Soviet Union formed an alliance of necessity during World War II. After the Axis powers were defeated, the two most powerful states in the world became the Soviet Union and the United States. Both federations were called the world's superpowers. The underlying geopolitical and ideological differences between the recent allies led to the confrontation known as the Cold War, which lasted from about 1947 to 1991. It began with the second Red Scare and it ended with the fall of the Soviet Union. At the dawn of the new era, the historian John Lewis Gaddis wrote: The new world of the post–Cold War era is likely to have few, if any, of these [Cold War] characteristics: that is an indication of how much things have already changed since the Cold War ended. We are at one of those rare points of 'punctuation' in history at which old patterns of stability have broken up and new ones have not yet emerged to take their place. Historians will certainly regard the years 1989–1991 as a turning point comparable in importance to the years 1789–1794, or 1917–1918, or 1945–1947; precisely what has 'turned,' however, is much less certain. We know that a series of geopolitical earthquakes have taken place, but it is not yet clear how these upheavals have rearranged the landscape that lies before us.
During this ripening period, the temperature and the level of humidity in the room where the cheese is aging is monitored to ensure the cheese does not spoil or lose its optimal flavor and texture. In general, the ripening temperature is around 8-10 degrees Celsius with a relative humidity of 85–95%, but this may differ according to the type of cheese being produced. At the beginning of this ripening process, the cheese loaves are punctured to create small openings to allow air to penetrate and support the growth of the aerobic Penicillium roqueforti cultures, thereby encouraging the formation of blue veins. Throughout the ripening process, the total ketone content is constantly monitored as the distinctive flavor and aroma of blue cheese arises from methyl ketones (including 2-pentanone, 2-heptanone, and 2-nonanone) which are a metabolic product of Penicillium roqueforti.
== Sources == Bath, Richard (ed.) The Complete Book of Rugby (Seven Oaks Ltd, 1997 ISBN 978-1-86200-013-1) ed. Brown, Archie; Kaser, Michael & Smith, Gerald S. (ed.s) The Cambridge Encyclopedia of Russia and the former Soviet Union, (2nd Ed., Cambridge University Press, Cambridge, England 1994; ISBN 0-521-35593-1) Cotton, Fran (Ed.) The Book of Rugby Disasters & Bizarre Records. (Compiled by Chris Rhys, Century Publishing, London, 1984). ISBN 0-7126-0911-3 Griffiths, John. Rugby's Strangest Matches: Extraordinary but true stories from over a century of rugby (Past Times/Robson Books, England; ISBN 978-1-86105-354-1) Hopkins, John (ed) Rugby (1979 ISBN 0-304-30299-6) Laidlaw, Chris From Twickers with Love: Rugby's Universal Message in Hopkins, John (ed) Rugby (1979 ISBN 0-304-30299-6) Richards, Huw A Game for Hooligans: The History of Rugby Union (Mainstream Publishing, Edinburgh, 2007, ISBN 978-1-84596-255-5) Riordan, James Sport in Soviet Society — development of sport and physical education in Russia and the USSR (Cambridge University Press, Cambridge, England, 1977) Sorokin, A.A. (А. А.
Sources: en.wikipedia.org
=== Myomesin 3 === Myomesin 3 is the least researched in the myomesin class due to it being the most recently discovered. It is encoded by the MYOM3 gene. It is located in the M6/M6' lines of the M-band and is expressed in intermediate skeletal muscles and adult cardiac muscles (specifically in the left ventricle and left atrium). MYOM3 is especially expressed in neonatal skeletal muscles, extraocular muscles, slow muscles, and IIA skeletal fibers. Myomesin 3 is the only member of the myomesin protein family to be completely absent from cardiac expression. Myomesin 3 displays an inverse relationship with myomesin 2.
Part of the Ring of Fire, a region of the world subject to earthquakes and volcanic eruptions, in the interior of Colombia the Andes are the prevailing geographical feature. Most of Colombia's population centers are located in these interior highlands. Beyond the Colombian Massif (in the southwestern departments of Cauca and Nariño), these are divided into three branches known as cordilleras (mountain ranges): the Cordillera Occidental, running adjacent to the Pacific coast and including the city of Cali; the Cordillera Central, running between the Cauca and Magdalena River valleys (to the west and east, respectively) and including the cities of Medellín, Manizales, Pereira, and Armenia; and the Cordillera Oriental, extending northeast to the Guajira Peninsula and including Bogotá, Bucaramanga, and Cúcuta. Peaks in the Cordillera Occidental exceed 4,700 m (15,420 ft), and in the Cordillera Central and Cordillera Oriental they reach 5,000 m (16,404 ft). At 2,600 m (8,530 ft), Bogotá is the highest city of its size in the world. The main rivers of Colombia are Magdalena, Cauca, Guaviare, Atrato, Meta, Putumayo and Caquetá. Colombia has four main drainage systems: the Pacific drain, the Caribbean drain, the Orinoco Basin and the Amazon Basin. The Orinoco and Amazon Rivers mark limits with Colombia to Venezuela and Peru respectively.
These compounds in some cells could actually promote the development of cancers or malignancies, and if that's the case then we need to be wary of them." A study by scientists from the Department of Dermatology, Bispebjerg Hospital, published in Mutation Research has concluded DHA 'induces DNA damage, cell-cycle block and apoptosis' in cultured cells. Many self tanners use chemical fragrances which may cause skin allergies or may trigger asthma. Furthermore, some of them contain parabens. Parabens are preservatives that can affect the endocrine system.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.